evaluating dual-targeting cd19/22 car-t cells in patients with r/r all
Published 1 year ago • 152 plays • Length 3:18Download video MP4
Download video MP3
Similar videos
-
2:42
dual-targeted anti-cd19/anti-cd20 car t-cells in r/r mcl: insights from a phase i/ii trial
-
2:32
phase i study of cd22-targeted car-t therapy in patients with cd19-negative b-all
-
3:28
the use of anti-cd19 car-t therapy for richter’s transformation
-
0:45
bispecific car t-cell therapy: combining anti-cd19 and cd22 car t-cells
-
2:19
anbal-cel: updated results from phase i study of novel cd19-targeting car-t therapy
-
1:26
emerging cd19-targeted car-t treatment approaches for nhls
-
1:33
novel dual-targeting cd19/22 car-t therapy in relapsed all
-
0:58
improving the long-term safety of cll treatment
-
1:39
out of specification anti-cd19 car t-cell products in aggressive b-cell lymphomas
-
1:21
anti-cd22 car t-cell therapy for all: trial update, utility for salvage and cd19 status
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
2:26
clinical data for cd19-directed car t-cell products in all
-
1:40
overcoming antigen escape following cd19-directed car-t therapy
-
3:01
mechanisms of antigen escape following cd19-directed car-t therapy
-
2:20
risk factors for success or failure of cd19-directed car-t therapy in children with b-all
-
1:52
opportunities and challenges for dual-targeting car-t therapy in all
-
7:19
checkpoint inhibitors augument cd19 car t-cell therapy in relapsed b-all
-
1:57
diminished chronic gvhd symptoms following anti-cd19 car t-cell therapy: a case study
-
3:38
mechanisms of resistance to car-t in all: t-cell fitness, antigen loss and immunological rejection